Gaborone — About 91 Batswana have enrolled in the HIV Prevention Trials Network (HPTN 084) (LIFE) study undertaken by Botswana-Harvard AIDS Institute Partnership.
The aim is to evaluate the safety and efficiency of the injectable cabotegravir (CAB LA) over the Truvada pill.
While the injectable agent is given once every two weeks, the pill is taken every day.
Speaking at a stakeholder engagement meeting, study physician Dr Alice Sehurutshi of the Botswana Harvard AIDS Institute Partnership said the research would enroll approximately 3 200 women aged between 18-45 years, who are at high risk of acquiring HIV in 20 sites across seven sub-Saharan countries including Botswana.
Dr Sehurutshi explained that, "The HPTN 084 is comparing the efficacy and safety of CAB LA to daily oral Truvada (TDF and FCT) for PrEP in HIV uninfected women in sub-Saharan Africa.
The HPTN 084 is thus a sister study to the HPTN 083, which is the first large-scale clinical trial of a long-acting injectable drug for HIV prevention in cisgender men and transgender women."
Dr Sehurutshi said comparing the HIV acquisition rates between the two study groups; the HPTN 083 study found that CAB LA regimen reduced the HIV incident rate by 69 per cent more than the daily oral regimen.
The study, she said, enrolled 4 570 study participants in Argentina, Brazil, India, Peru, South Africa, the United States and Vietnam.
Two-thirds of the participants were under 30 years of age and 12 per cent were transgender women, she added.
In addition, she stated that of the 50 incident HIV infections that occurred during the study, there were 38 incident infections in the TDF/FCT arm; three times higher than the number of incident HIV infections in the CAB arm, which recorded only 12 incident infections.
Overall, she noted, the results indicated that CAB LA was highly effective for the prevention of HIV acquisition in cisgender men and transgender women.
Dr Sehurutshi described the injectable regimen as a milestone in the pursuit of innovative HIV prevention strategies. BOPA
<i>Source : BOPA</i>